Placebo Causes Adverse Reaction With Industry, Raises Regulatory Concerns
This article was originally published in The Tan Sheet
An inert sugar pill marketed as a placebo for ailing children will likely attract regulatory interest from the Federal Trade Commission as well as FDA, according to industry experts
You may also be interested in...
An American Academy of Pediatrics report recommending prescribing statin drugs for cardiovascular disease in children could present another roadblock for switching statins to OTC
In late 2006, the Council for Responsible Nutrition and the Dietary Supplement Education Alliance both shared plans for media campaigns aimed at building consumer confidence in the supplement industry
The "good news, bad news" format FDA has adopted for qualified health claims seems "unlikely to provide consumers with a good understanding of the nature of the support that exists for the statement or the reasons for FDA's unfavorable view of the claim," according to the Council for Responsible Nutrition